Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial.
Alejandro Morales-OrtegaAna Isabel Farfán-SedanoJuan Víctor San Martín-LópezAlmudena Escribá-BárcenaBeatriz Jaenes-BarriosElena Madroñal-CerezoCristina Llarena-BarrosoNieves Mesa-PlazaBegoña Frutos-PérezJosé Manuel Ruiz-GiardínMiguel Ángel Duarte-MillánSara Isabel Piedrabuena-GarcíaLorena Carpintero-GarcíaEduardo Canalejo-CastrilleroBelén Mora-HernándezCarlos Javier García-ParraHéctor Agustín Magro-GarcíaAlicia Algaba-GarcíaBelén Hernández-MuniesaBerta Nasarre-LópezAna Ontañón-NasarreMaría Jesús Domínguez-GarcíaDulce Gómez-SantosSantiago Prieto-MencheroJaime García de TenaFernando BermejoMario García-GilSonia Gonzalo-PascuaDavid Bernal-Bellonull nullPublished in: Journal of medical virology (2023)
Baricitinib plus standard care showed better results for hospitalized COVID-19 patients, being the most advantageous therapeutic strategy among those proposed in this exploratory clinical trial. This article is protected by copyright. All rights reserved.